ReviewArchives of gynecology and obstetrics2016
Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.
Review in Archives of gynecology and obstetrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Guideline
- Efficacy of Dequalinium Chloride vs Metronidazole for the Treatment of Bacterial Vaginosis: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Accurate 16S Absolute Quantification Sequencing Revealed Vaginal Microecological Composition and Dynamics During Mixed Vaginitis Treatment With Fufang FuRong Effervescent Suppository.Frontiers in cellular and infection microbiology · 2022Trial
- Vaginal tablets of dequalinium chloride 10 mg versus clotrimazole 100 mg for vaginal candidiasis: a double-blind, randomized study.Archives of gynecology and obstetrics · 2021Trial
- Selective elimination of quiescent cancer cells by dequalinium chloride via ROS-mediated ferroptosis.FEBS open bio · 2026Article
- Longitudinal Clinical and Microscopic Findings After Dequalinium Chloride Treatment in Vulvovaginal Infections: A Retrospective Real-World Study from Mexican Gynecological Practice.Journal of clinical medicine · 2026Article
- The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage.Cell reports · 2026Article
- A novel class of small-molecule inhibitors targeting bacteriophage infection.RSC chemical biology · 2026Article
- Nanogel-based delivery of dequalinium chloride: A novel approach for antimicrobial and controlled drug release.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage.bioRxiv : the preprint server for biology · 2025Article
- Lysozyme-dequalinium encapsulation in a Zn-Fe LDH-chia seed matrix for enhanced antimicrobial dental therapeutics.RSC advances · 2025Article
- Review
- Dequalinium Chloride-An Emerging Option in the Sparse Landscape of Bacterial Vaginosis Therapies.JAMA network open · 2024Article
- Toxic Effects of Penetrating Cations.Membranes · 2023Review
- Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods.Journal of clinical medicine · 2023Review
- Fighting polymicrobial biofilms in bacterial vaginosis.Microbial biotechnology · 2023Review
- Drugging evolution of antibiotic resistance at a regulatory network hub.Science advances · 2023Article
- Tackling antibiotic resistance by inducing transient and robust collateral sensitivity.Nature communications · 2023Article
- Bolaamphiphile Analogues of 12-bis-THA ClmSphere · 2023Article
- Bacterial vaginosis: a review of approaches to treatment and prevention.Frontiers in reproductive health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaginal infections are responsible for a large proportion of gynaecological outpatient visits. Those are bacterial vaginosis (BV), vulvovaginal candidosis (VVC), aerobic vaginitis (AV) associated with aerobic bacteria, and mixed infections. Usual treatments show similar acceptable short-term efficacy, but frequent recurrences and increasing microbial resistance are unsolved issues. Furthermore, vaginal infections are associated with a variety of serious adverse outcomes in pregnancy and generally have a major impact on quality of life. Identifying the correct therapy can be challenging for the clinician, particularly in mixed infections.
findingsDequalinium chloride (DQC) is an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity. Systemic absorption after vaginal application of DQC is very low and systemic effects negligible. Vaginal DQC (Fluomizin vaginal tablets) has been shown to have equal clinical efficacy as clindamycin in the treatment of BV. Its broad antimicrobial activity makes it appropriate for the treatment of mixed vaginal infections and in case of uncertain diagnosis. Moreover, resistance of pathogens is unlikely due to its multiple mode of action, and vaginal DQC provides also a reduced risk for post-treatment vaginal infections.
conclusionsVaginal DQC (10 mg) as 6-day therapy offers a safe and effective option for empiric therapy of different vaginal infections in daily practice. This review summarizes the available and relevant pharmacological and clinical data for the therapy of vaginal infections with vaginal DQC and provides the rationale for its use in daily gynaecologic practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.